Form 4: Vivos Therapeutics Director Anja B. Krammer Acquires Stock Options

Director Anja B. Krammer acquired 4,000 stock options in Vivos Therapeutics, Inc. on June 20, 2024.

Summary

• On June 28, 2024, a Form 4 filing was submitted to the SEC regarding Anja B. Krammer, a Director of Vivos Therapeutics, Inc.
• The filing reports a transaction that occurred on June 20, 2024, where Ms. Krammer acquired 4,000 stock options.
• The exercise price of these options is $2.38.
• One-half of the options vested immediately, one-fourth will vest on September 30, 2024, and one-fourth will vest on December 31, 2024.
• Following the reported transaction, Ms. Krammer directly owns 7,067 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't necessarily indicate a significant shift in the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Stakeholder Impact

• Shareholders may view the stock option grant as a sign of confidence from a director in the company's future performance.

Key Dates